Methylprednisolone hemisuccinate

Generic Name: Methylprednisolone hemisuccinate

Brand Names: Solu-medrol

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₄O_₈

CAS Number: 2921-57-5

Unique Ingredient Identifier: 5GMR90S4KN

Background: A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Associated Conditions: Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis

Associated Therapies: Palliative Treatment

Clinical Trials

Glucocorticoid Inflammation Paradox in Human Skeletal Muscle

Phase 3

Withdrawn

Conditions: Aging

Interventions: Drug: Methylprednisolone

First Posted Date: 2018-05-18

Last Posted Date: 2020-03-11

Lead Sponsor: Texas A&M University

Registration Number: NCT03529929

Locations: 🇺🇸
Texas A&M University, College Station, Texas, United States

CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid

Not Applicable

Terminated

Conditions: Systemic Lupus Erythematosus (SLE)

Interventions: Drug: Cyclophosphamide
Drug: Methylprednisolone
Drug: Prednisone
Drug: Mycophenolate Mofetil

First Posted Date: 2018-04-10

Last Posted Date: 2021-07-21

Lead Sponsor: University of Sao Paulo General Hospital

Target Recruit Count: 49

Registration Number: NCT03492255

Locations: 🇧🇷
Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil
🇧🇷
Hospital das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil

Preoperative High Dose Steroids for Liver Resection- Effect on Complications in the Immediate Postoperative Period

Phase 4

Completed

Conditions: Complication, Postoperative

Interventions: Drug: Dexamethasone
Drug: Methylprednisolone

First Posted Date: 2018-01-18

Last Posted Date: 2021-01-05

Lead Sponsor: Rigshospitalet, Denmark

Target Recruit Count: 174

Registration Number: NCT03403517

Locations: 🇩🇰
Rigshospitalet, Copenhagen, Denmark

Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)

Not Applicable

Recruiting

Conditions: Childhood Acute Lymphoblastic Leukemia

Interventions: Drug: Dexamethasone intermittent
Drug: Dexamethasone continuous
Drug: Second phase of induction
Drug: Standard induction therapy
Drug: Standard consolidation therapy
Drug: Dexamethasone
Drug: Methylprednisolone
Drug: Idarubicin
Drug: Daunorubicin
Drug: Bortezomib

First Posted Date: 2018-01-04

Last Posted Date: 2020-02-05

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 4000

Registration Number: NCT03390387

Locations: 🇷🇺
Morozov Children's Municipal Clinical Hospital, Moscow, Russian Federation
🇦🇲
prof. R.O.Eolyan Hematology Center, Ereván, Armenia
🇷🇺
Transbaikal Regional Oncology Dispensary, Chita, Russian Federation

and more 45 locations

Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation

Phase 2

Completed

Conditions: Antibody-mediated Rejection
Lung Transplant Rejection

Interventions: Drug: Tacrolimus
Drug: Belatacept
Drug: ATG
Drug: Mycophenolate Mofetil
Drug: Methylprednisolone
Drug: Prednisone

First Posted Date: 2018-01-02

Last Posted Date: 2022-11-25

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 27

Registration Number: NCT03388008

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Houston Methodist Hospital, Houston, Texas, United States

A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)

Phase 2

Terminated

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Dietary Supplement: D-aspartate
Drug: Placebo
Biological: IFN beta-1a
Drug: Methylprednisolone

First Posted Date: 2017-12-29

Last Posted Date: 2020-02-10

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 7

Registration Number: NCT03387046

Locations: 🇮🇹
Ospedale P.A.Micone, Genova, Italy
🇮🇹
Azienda Ospedaliera Sant'Andrea-Università di Roma La Sapienza, Roma, Italy
🇮🇹
Ospedale Binaghi, Università di Cagliari,ASL 8, Cagliari, Italy

and more 14 locations

Procollagen-3 Driven Corticosteroids for Persistent Acute Respiratory Distress Syndrome

Phase 3

Terminated

Conditions: Persistent ARDS

Interventions: Drug: Methylprednisolone placebo
Drug: Methylprednisolone

First Posted Date: 2017-12-13

Last Posted Date: 2024-01-03

Lead Sponsor: Assistance Publique Hopitaux De Marseille

Target Recruit Count: 21

Registration Number: NCT03371498

Locations: 🇫🇷
Assistance Publique Hôpitaux de Marseille, Marseille, France

A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT

Phase 3

Active, not recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Alemtuzumab GZ402673
Drug: Glatiramer acetate
Drug: Beta-Interferon
Drug: Methylprednisolone
Drug: Ranitidine
Drug: Ceterizine
Drug: Dexchlorpheniramine
Drug: Paracetamol
Drug: Acyclovir
Drug: Prednisolone
Drug: Diphenydramine
Drug: Other H1 antagonist

First Posted Date: 2017-12-11

Last Posted Date: 2023-09-21

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 16

Registration Number: NCT03368664

Locations: 🇹🇷
Investigational Site Number :7920002, Ankara, Turkey
🇹🇷
Investigational Site Number :7920001, Ankara, Turkey
🇫🇷
Investigational Site Number :2500002, Strasbourg, France

and more 18 locations